Posted by Michael Wonder on 27 Jul 2016
NICE publishes final guidance on the use of nivolumab in combination with ipilimumab for treating advanced melanoma
27 July 2016 - NICE publishes further guidance on the use of nivolumab (Opdivo) in patients wth melanoma.
Nivolumab, in combination with ipilimumab is recommended, within its marketing authorisation, as an option for treating advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with the discount agreed in the patient access scheme.
Nivolumab was registered by the EMA for use in combination with ipilimumab on 11 May 2016.
